Outer Membrane Protein A (OmpA) of Shigella Flexneri 2a Links Innate and Adaptive Immunity in a TLR2-dependent Manner and Involvement of IL-12 and Nitric Oxide
Overview
Affiliations
We determine that OmpA of Shigella flexneri 2a is recognized by TLR2 and consequently mediates the release of proinflammatory cytokines and activates NF-κB in HEK 293 cells transfected with TLR2. We also observe that in RAW macrophages TLR2 is essential to instigate the early immune response to OmpA via NF-κB activation and secretion of cytokines and NO. Consistent with these results, TLR2 knockdown using siRNA abolishes the initiation of immune responses. Processing and presentation of OmpA depend on TLR2; MHCII presentation of the processed antigen and expression of CD80 significantly attenuated in TLR2 knockdown macrophages. The optimum production of IFN-γ by the macrophages:CD4(+) T cells co-culture depends on both TLR2 activation and antigen presentation. So, TLR2 is clearly recognized as a decisive factor in initiating host innate immune response to OmpA for the development of CD4(+) T cell adaptive response. Furthermore, we demonstrate in vivo that intranasal immunization of mice with OmpA selectively enhances the release of IFN-γ and IL-2 by CD4(+) T cells. Importantly, OmpA increases the level of IFN-γ production in Ag-primed splenocytes. The addition of neutralizing anti-IL-12p70 mAb to cell cultures results in the decreased release of OmpA-enhanced IFN-γ by Ag-primed splenocytes. Moreover, coincubation with OmpA-pretreated macrophages enhances the production of IFN-γ by OmpA-primed CD4(+) T cells, representing that OmpA may enhance IFN-γ expression in CD4(+) T cells through the induction of IL-12 production in macrophages. These results demonstrate that S. flexneri 2a OmpA may play a critical role in the development of Th1 skewed adaptive immune response.
Li R, Liu J, Wen C, Shi Y, Ling J, Cao Q Sci Adv. 2023; 9(34):eadg9601.
PMID: 37624881 PMC: 10456869. DOI: 10.1126/sciadv.adg9601.
Shigella Outer Membrane Vesicles as Promising Targets for Vaccination.
Qasim M, Wrage M, Nuse B, Mattner J Int J Mol Sci. 2022; 23(2).
PMID: 35055181 PMC: 8781765. DOI: 10.3390/ijms23020994.
Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
Kumar S, Sunagar R, Gosselin E Front Immunol. 2019; 10:1144.
PMID: 31191528 PMC: 6549121. DOI: 10.3389/fimmu.2019.01144.
Bae E, Seo S, Kim C, Jang M, Song M, Lee T J Innate Immun. 2019; 11(4):316-329.
PMID: 30844806 PMC: 6738265. DOI: 10.1159/000494098.
Yanagisawa N, Ueshiba H, Abe Y, Kato H, Higuchi T, Yagi J Int J Mol Sci. 2018; 19(10).
PMID: 30347705 PMC: 6214128. DOI: 10.3390/ijms19103241.